2021 continued the strong momentum in the deal markets that began after the first lockdown was lifted in mid-2020. Businesses returned to M&A in growing numbers as they found ways to cope with supply chain disruptions and uncertainty. This was not simply a recovery in deal activity, however: the number of deals in Switzerland surpassed pre-pandemic levels to hit a record high last year. 

Would-be buyers and sellers find themselves in an increasingly competitive market that is buoyed further by extremely low financing costs and plenty of liquidity in the market. Though prices remain high as valuation multiples are boosted in lockstep with strong financial market performances, there will be no slowdown in activity in 2022. Look out for two areas in particular: digitalization and sustainability. Targets with potential in these fields will be in high demand. 

Your guide to the Swiss M&A landscape

You will find content in three sections: deal statistics from last year, our insights into each sector including the most notable transactions and what drove deal activity, and a full list of all deals that involved Swiss businesses.

M&A and the innovation renaissance in Life Sciences

Ground-breaking innovation in Life Sciences has accelerated at a breath-taking pace since the onset of the pandemic, particularly across diagnostics and the development and distribution of vaccines. As the sector’s leading players in Switzerland ramp up their efforts to continue securing new sources of innovation and technology through M&A, we explore which areas of Life Sciences are seeing the biggest surge in interest, and why.

Talk to our experts

M&A transactions are becoming more complex than ever. Fresh challenges and questions are constantly arising that can fundamentally affect the success of your deal. Whether you are looking to acquire, divest, merge or restructure, KPMG’s multi-disciplinary Deal Advisory team has the expertise and hands-on experience to support you – from developing your strategy through to successful implementation. 

Timo Knak

Partner, Head of Deal Advisory and Head of Mergers & Acquisitions

> Contact me

Roger van den Heuvel

Partner, EMA Life Sciences Strategy Lead
 

> Contact me

Discover more

Access our insights into what is happening in the deal markets, how deal-making is advancing through the use of data analytics, and a host of other resources that are relevant to anyone active in M&A today.